Background: Extrathoracic malignancies metastasize to the mediastinum and/or pulmonary hilum. Mediastinoscopy and thoracoscopy are standard to obtain tissue proof of metastatic spread but are invasive. Endobronchial ultrasound with real-time-guided transbronchial fine-needle aspiration (EBUS-TBNA) is a minimally invasive alternative for surgical staging of lung cancer.
The lungs and mediastinum represent one of the most frequent sites for malignant metastasis. Large series of autopsies have shown the lung to be the second most common site for the occurrence of metastasis [1] . Tumours can spread to the lung through hematogenous or lymphangitic routes. Tumours most prone to spread to the chest include breast carcinoma, colorectal carcinoma, renal cell carcinoma and melanoma. Patients with pulmonary metastasis most often present with a new radiological finding either on chest X-ray or computed tomography (CT) scan without associated respiratory symptoms. In many situations, the diagnosis of lung metastasis is all too obvious from the clinical scenario, and obtaining confirmatory tissue is unnecessary. However, tissue diagnosis is felt necessary especially in case of solitary pulmonary lesions or suspicious isolated hilar/mediastinal lymph nodes. The different scenarios are then (i) initial staging before any treatment is given in order to differentiate from alternative (benign or secondary malignant) diagnoses or (ii) obtaining a tissue proof of disease relapse after a previous radical treatment with curative intent. In case a regular bronchoscopy is not contributive, a surgical approach of the mediastinum or hilum by means of a mediastinoscopy or a video-assisted thoracoscopic surgical procedure is indicated. Although these are established methods, their invasiveness, need for general anaesthesia and costs are often appreciated hurdles.
Endobronchial ultrasound with real-time-guided transbronchial fine-needle aspiration (EBUS-TBNA) is a minimally invasive outpatient procedure by which mediastinal [2] and hilar lymph nodes [3] as well as centrally located primary lung lesions [4] can be visualised and sampled under ultrasound guidance. In a systematic review, EBUS-TBNA has shown a pooled sensitivity of 93% in the staging of non-small-cell lung cancer. In a direct comparison with surgical staging, EBUS-TBNA even showed to be superior [5] . Therefore, EBUS-TBNA has been adopted in the most recent lung cancer staging guidelines as a minimally invasive alternative to surgical staging [6] . Previous case reports indicated that EBUS-TBNA might also be useful to provide tissue proof of mediastinal or hilar spread in patients with concurrent or previously treated extrathoracic malignancies [7, 8] Immunohistochemical staining with an antibody to the oestrogen and progesterone receptor, cytokeratins (e.g. CK7 and CK20), CD10, thyroid transcription factor-1, prostate-specific antigen or S-100 protein was used whenever this was needed for tumour origin identification. If the pathology of the EBUS-TBNA samples resulted in a formal diagnosis, this was judged as a true-positive finding. No further tissue confirmation was requested in these cases, as it was judged not ethical to confirm positive findings with additional invasive diagnostic tests. Patients in whom EBUS-TBNA did not unequivocally show the presence of malignancy or an alternate diagnosis other than benign findings were referred for additional investigations including surgical procedures such as thoracoscopy, mediastinoscopy or thoracotomy to obtain a reference pathology result. Follow-up with imaging was used if the clinician judged this was sufficient.
statistical analysis
A descriptive statistical analysis of the test performance of EBUS-TBNA in the patients in whom a formal pathology was available was carried out with SPSS 17.0 (SPSS Inc., Chicago, IL).
results
We analysed 92 consecutive patients whom were referred for a tissue diagnosis of a newly found intrathoracic lesion. These were suspect to be a hematogenic or lymphogenic metastasis of a concurrent (36%) or a previously diagnosed and treated (64%) extrathoracic malignancy. The characteristics of the patients are shown in Table 1 . Head and neck, colorectal, breast and renal cell carcinoma represented almost 70% of the malignancies included.
In Table 2 , the characteristics of the intrathoracic lesions are shown. In 10 patients (11%), a central parenchymatous lesion was found, while in 85 (92%) there was a suspicion for lymphogenic metastasis. The lymph nodes were distributed in the hilar regions (46%) or in the mediastinum (paratracheal or subcarinal node present in 71%). 18-Fluorodeoxyglucose positron emission tomography scan was available in 73% (positive in 97%), while in the others the size of the lymph node or just the presence of the lung lesion explained the clinical suspicion for metastasis. The median size of the lung lesions was 30 mm (range 20-50 mm) while that of the GIST, gastrointestinal stromal cancer. 
Twenty-seven patients (29%) underwent a preceding flexible videobronchoscopy; endobronchial mucosal abnormalities were not present and all these procedures did not provide a formal diagnosis. In Figure 1 , the results of the EBUS procedure and the final diagnoses are shown. A median of four needle passes (range 1-7) were done per patient. Tissue proof of intrathoracic malignancy was found in 52 patients (57%) [metastasis of extrathoracic malignancy in 40 (44%) and second malignancy (lung cancer) in 12 (13%)]. In four patients, EBUS-TBNA showed non-caseating granulomas and giant cells in the biopsied lymph nodes suggestive for sarcoidosis or sarcoid-like reaction. In 36 (39%) patients, the biopsies showed either normal lymphocytes (35%) or not-representative material (4%). In nine of these patients (25%), metastatic disease was found by confirmatory surgical procedures. In 25 patients, the EBUS-TBNA findings suggesting benign lesions were confirmed either by clinical and radiological follow-up (n = 14, median 7 months, range 3-14) or surgical procedures (n = 11). In two patients, neither pathology nor clinicoradiological follow-up was available.
The final diagnosis of the intrathoracic lesions showed malignancy in 61 of the 90 patients in whom a final result was available (prevalence 68%). The sensitivity and negative predictive value to detect malignancy were 85% [95% confidence interval (CI) 73-93] and 76% (95% CI 59-88).
In an additional analysis, assuming that all patients in whom no surgical verification was done were also false negative [n = 16; 14 had only a clinicoradiological follow-up and 2 had no follow-up at all], the sensitivity of EBUS-TBNA for malignant disease was 68% (95% CI 55-77) with a negative predictive value of 38% (95% CI 22-54).
A scheduled surgical procedure (diagnostic mediastinoscopy, video-assisted thoracoscopic surgery) or transthoracic puncture could be cancelled in 61% representing the impact of EBUS-TBNA on the diagnostic management in these patients.
One complication occurred during EBUS-TBNA: a respiratory depression with desaturation. Abortion of the procedure resulted in a full recovery.
discussion
In patients with (concurrent or previously treated) extrathoracic malignancy, EBUS-TBNA has a sensitivity of 85% to demonstrate metastatic spread. Implementation of EBUS-TBNA in these patients obviates invasive surgical diagnostic procedures in 61%.
Although the diagnosis of lung metastasis is often all too obvious from the clinical scenario, tissue diagnosis of centrally located solitary pulmonary lesions or isolated suspicious hilar/mediastinal lymphadenopathies is a frequently encountered problem. Two categories are discerned: both in patients with previously diagnosed and treated extrathoracic malignancy as in patients with concurrently diagnosed extrathoracic cancer, the differentiation between a metastasis, a second primary tumour (lung cancer) or a benign disease is relevant and has therapeutic and prognostic implications. Flexible bronchoscopy and CT/ultrasound-guided transthoracic needle biopsy are probably the most commonly used techniques to obtain a tissue diagnosis in these cases. Whereas the former has a good yield for exophytic endobronchial lesions, the latter is commonly deployed for subpleural peripheral lung lesions. Mediastinal or hilar small-or largesized lesions-but without endobronchial abnormality visible-remain a challenge since neither a routine bronchoscopy nor a transthoracic needle biopsy carry out well in these patients [9, 10] . Although surgical approaches (including mediastinoscopy and video-assisted thoracoscopy) are established to obtain a tissue diagnosis, minimally invasive techniques such as endoscopic ultrasound with real-time-guided needle biopsy might be a valuable alternative. The reason is that 
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both EBUS-TBNA and transoesophageal endoscopic ultrasound with fine-needle aspiration (EUS-FNA) have a high sensitivity and accuracy for staging of mediastinal lymph nodes in patients with lung cancer [11] [12] [13] . In addition, EUS-FNA or EBUS-TBNA can obtain tissue diagnosis of centrally located intrapulmonary lesions invisible with a routine bronchoscopy [4, 14] . A few case reports on EBUS-TBNA [7, 8] and one single series on EUS-FNA [15] recently indicated the usefulness to show intrathoracic metastasis of extrathoracic malignancies with endoscopic ultrasound-guided fine-needle biopsies. The potential advantage of EBUS-TBNA over EUS-FNA is obvious in these indications since the former has a bilateral mediastinal and hilar reach, while the latter reaches only the left paratracheal and subcarinal/paraoesophageal mediastinal lymph node stations.
To our knowledge, this is the first report that evaluates the value of EBUS-TBNA for the diagnosis of lesions in patients with (concurrent or previous) extrathoracic malignancies. The test performance characteristics are slightly lower than what has been reported for the diagnosis and staging of mediastinal lymph nodes in patients with lung cancer [16] . There may be several reasons for this. First, the approach to some hilar lesions is not always easy, and anatomical factors such as the interposition of large vessels or aerated tissue can interfere with the puncture. Especially upper lobe lesions, lesions located too peripherally or strictly paraoesophageal lymph nodes below the subcarinal space can be out of reach of the scope making the selection of the patient a crucial issue. EUS-FNA has a complementary reach to EBUS-TBNA and might offer an alternative in some cases. Secondly, the histopathological analysis of various extrathoracic malignancies might be more difficult as compared with lung cancer samples. It is worth noticing that immunohistochemical stainings, especially on cell-block preparations, can help the cytopathologist. In the current series, immunohistochemistry was carried out on 47% of the samples and contributed to the diagnosis in 79% of these. Besides the diagnosis of malignancy, an alternative diagnosis (sarcoidosis) was found in four patients. It has been shown before that endoscopic ultrasound is useful for diagnosing granulomatous diseases [17] [18] [19] , but one should be aware that granulomatous reactions can be present in the neighbourhood of tumoral lesions and metastasis [20] . Nevertheless, the presence of non-caseating granulomas and giant cells in the mediastinal or hilar lymph nodes might justify a clinical follow-up rather than an invasive surgical procedure. In 36 patients (39%), the cytopathologist was unable to provide a formal diagnosis. In nine of these patients (25%), metastatic disease was found upon confirmatory procedures or follow-up. There was not a particular tumour type prone for this false-negative result of EBUS-TBNA. These data translate in a negative predictive value of 76% and justify the recommendation for a confirmatory intervention.
EBUS-TBNA has been considered a safe procedure, although seldom case reports with infectious complications have been published [21] . We report on one patient with a respiratory depression and desaturation. The patient had chronic obstructive airway disease and was sedated with midazolam and fentanyl. Abortion of the procedure resulted in a full recovery without further intervention needed.
It should be noted that several limitations apply to this report. First, the retrospective character of the study implies a selection bias of the investigators allowing the patient for EBUS-TBNA. A prospective study with well-defined inclusion and exclusion criteria could overcome this. Secondly, this series does not give an answer on where in the staging algorithm EBUS-TBNA should be deployed. Especially the role of a preceding bronchoscopy (if possible added with an unguided or blind TBNA) was not addressed here. Blind TBNA remains a poorly used endoscopic tool [22] and will probably remain so with the advent of guided biopsy tools. Finally, we used a composite gold standard for the negative findings upon EBUS-TBNA. In some patients, a surgical verification was done, while in others a clinical follow-up was judged by the clinician. Therefore, we also reported on a worst-case scenario that underscored the reported findings.
In conclusion, EBUS-TBNA is an accurate, minimally invasive and safe staging procedure and can be considered the procedure of choice for patients with extrathoracic malignancies in whom hilar or mediastinal lesions are observed.
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